$18.35 Million in Sales Expected for CytomX Therapeutics, Inc. (NASDAQ:CTMX) This Quarter

Brokerages predict that CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Rating) will post $18.35 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for CytomX Therapeutics’ earnings. The lowest sales estimate is $15.41 million and the highest is $25.00 million. CytomX Therapeutics reported sales of $16.29 million during the same quarter last year, which would suggest a positive year over year growth rate of 12.6%. The business is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that CytomX Therapeutics will report full year sales of $73.74 million for the current year, with estimates ranging from $63.36 million to $100.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $79.75 million, with estimates ranging from $69.26 million to $100.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMXGet Rating) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). CytomX Therapeutics had a negative return on equity of 83.08% and a negative net margin of 129.97%. During the same period in the prior year, the firm earned ($0.26) earnings per share.

A number of equities analysts recently commented on CTMX shares. StockNews.com raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of CytomX Therapeutics in a report on Friday, March 4th. Wedbush decreased their price target on CytomX Therapeutics from $10.00 to $6.00 and set an “outperform” rating on the stock in a report on Tuesday, May 10th. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 13th. Finally, JPMorgan Chase & Co. decreased their price target on CytomX Therapeutics from $10.00 to $9.00 and set an “overweight” rating on the stock in a report on Wednesday, March 2nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, CytomX Therapeutics has an average rating of “Buy” and an average target price of $9.54.

Shares of CytomX Therapeutics stock opened at $1.69 on Friday. CytomX Therapeutics has a one year low of $1.51 and a one year high of $8.63. The stock’s fifty day moving average is $2.34 and its 200 day moving average is $4.12.

Several institutional investors have recently modified their holdings of CTMX. Macquarie Group Ltd. grew its position in CytomX Therapeutics by 515.1% in the third quarter. Macquarie Group Ltd. now owns 4,853 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 4,064 shares in the last quarter. Mackenzie Financial Corp bought a new stake in shares of CytomX Therapeutics during the first quarter valued at approximately $35,000. Delphia USA Inc. bought a new stake in shares of CytomX Therapeutics during the first quarter valued at approximately $39,000. Lazard Asset Management LLC bought a new stake in shares of CytomX Therapeutics during the first quarter valued at approximately $40,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of CytomX Therapeutics during the fourth quarter valued at approximately $44,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

CytomX Therapeutics Company Profile (Get Rating)

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

Further Reading

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.